Market Overview

UPDATE: Barclays Raises PT to $57 on CVS Caremark Following Meeting with Management

Share:
Related CVS
UPDATE: CVS Health Beats Q4 Views
Earnings Scheduled For February 10, 2015
Cardinal Health Set to Buy Cordis, Shares Hit 52-Week High - Analyst Blog (Zacks)

Barclays reiterated its Overweight rating on CVS Caremark (NYSE: CVS) and raised its price target from $54 to $57.

Barclays noted, "At CVS Caremark's 2012 analyst meeting, management showed investors how the company's business model gives it meaningful competitive advantages as the US healthcare industry is transformed. [P]erhaps most significant, is the change in rationale for payments to healthcare providers, especially doctors and hospitals, as the nation moves from fee-for-service to outcomes-based payment. We see many approaches to pay-for-performance, but encouraging patients to remain adherent to their medications is crucial to all of them."

CVS Caremark closed at $49.24 on Friday.

Latest Ratings for CVS

DateFirmActionFromTo
Feb 2015Deutsche BankMaintainsHold
Feb 2015CitigroupMaintainsNeutral
Jan 2015Goldman SachsUpgradesNeutralBuy

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: BarclaysAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (CVS)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→